ReviewEuropean respiratory review : an official journal of the European Respiratory Society2020
How can we minimise the use of regular oral corticosteroids in asthma?
Review in European respiratory review : an official journal of the European Respiratory Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pediatric Outpatient Prescriptions in Countries With Advanced Economies in the 21st Century: A Systematic Review.JAMA network open · 2022Pooled it
- Dupilumab efficacy by disease severity in pediatric type 2 asthma.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Trial
- Early response toward clinical remission with dupilumab in severe asthma: Real-world cohort.The journal of allergy and clinical immunology. Global · 2026Article
- Costs of Oral Corticosteroid Use in Patients with Severe Asthma With/Without Chronic Rhinosinusitis with Nasal Polyps: Data from the Italian SANI Registry.Advances in therapy · 2025Article
- Prevalence, Change and Burden of Systemic Corticosteroid Use in Type 2 Inflammation Associated Diseases Over 25 Years - A Nationwide Danish Study.Journal of asthma and allergy · 2025Article
- Non-episodic angioedema with eosinophilia as a differential diagnosis of eosinophilia in young females.The World Allergy Organization journal · 2024Article
- Consensus on the management of united airways disease with type 2 inflammation: a multidisciplinary Delphi study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- Allergic Sensitization Driving Immune Phenotyping and Disease Severity in a Mouse Model of Asthma.Allergy, asthma & immunology research · 2023Article
- Multiple Biologics for Multiple T2 Diseases: A Pharmacoepidemiological Algorithm for Sorting Out Patients by Indication.Journal of asthma and allergy · 2023Article
- Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.Frontiers in immunology · 2023Review
- Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma.The World Allergy Organization journal · 2022Review
- Over-prescription of short-acting βAsthma research and practice · 2022Article
- Clinical Characteristics and Disease Burden of Severe Asthma According to Oral Corticosteroid Dependence: Real-World Assessment From the Korean Severe Asthma Registry (KoSAR).Allergy, asthma & immunology research · 2022Article
- Personalized Management of Patients with Chronic Rhinosinusitis with Nasal Polyps in Clinical Practice: A Multidisciplinary Consensus Statement.Journal of personalized medicine · 2022Review
- Reducing Tolerance for SABA and OCS towards the Extreme Ends of Asthma Severity.Journal of personalized medicine · 2022Review
- Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2022Review
- Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma.Drug design, development and therapy · 2022Article
- Real world effectiveness of benralizumab on respiratory function and asthma control.Multidisciplinary respiratory medicine · 2021Article
- Perspectives on decisions for treatment and care in severe asthma.The World Allergy Organization journal · 2021Review
- Childhood asthma heterogeneity at the era of precision medicine: Modulating the immune response or the microbiota for the management of asthma attack.Biochemical pharmacology · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Options to achieve oral corticosteroid (OCS)-sparing have been triggering increasing interest since the 1970s because of the side-effects of OCSs, and this has now become achievable with biologics. The Société de Pneumologie de Langue Française workshop on OCSs aimed to conduct a comprehensive review of the basics for OCS use in asthma and issue key research questions. Pharmacology and definition of regular use were reviewed by the first working group (WG1). WG2 examined whether regular OCS use is associated with T2 endotype. WG3 reported on the specificities of the paediatric area. Key "research statement proposals" were suggested by WG4. It was found that the benefits of regular OCS use in asthma outside episodes of exacerbations are poorly supported by the existing evidence. However, complete OCS elimination couldn't be achieved in any available studies for all patients and the panel felt that it was too early to conclude that regular OCS use could be declared criminal. Repeated or prolonged need for OCS beyond 1 g·year
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.